Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: A systematic review

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 20997-21010

  Abelló, David ^a   Sancho, Elena ^a   Camps, Jordi ^a,b   Joven, Jorge ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

Atherosclerosis; Coronary artery disease; Myocardial infarction; Oxidative stress; Paraoxonase; Systematic review

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; HIGH DENSITY LIPOPROTEIN; PON1 PROTEIN, HUMAN; PON2 PROTEIN, HUMAN; PON3 PROTEIN, HUMAN;

ATHEROMA; ATHEROSCLEROSIS; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENZYME ACTIVITY; GENE; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HUMAN; OXIDATIVE STRESS; PON GENE; REVIEW; SYSTEMATIC REVIEW; ANIMAL; CORONARY BLOOD VESSEL; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY VESSELS; HUMANS; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; POLYMORPHISM, GENETIC;

EID: 84910116486     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151120997     Document Type: Review

References (60)

1. Primo-Parmo, S.L.; Sorenson, R.C.; Teiber, J.; La Du, B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33, 498-507.
2. Sorenson, R.C.; Primo-Parmo, S.L.; Camper, S.A.; La Du, B.N. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics 1995, 30, 431-438.
3. Gupta, N.; Gill, K.; Singh, S. Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J. Med. Res. 2009, 130, 361-368.
4. Adkins, S.; Gan, K.N.; Mody, M.; La Du, B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 1993, 52, 598-608.
5. She, Z.-G.; Chen, H.-Z.; Yan, Y.; Li, H.; Liu, D.-P. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid. Redox Signal. 2012, 16, 597-632.
6. Camps, J.; Marsillach, J.; Joven, J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 2009, 46, 83-106.
7. Hine, D.; Mackness, B.; Mackness, M. Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life. 2012, 64, 157-161.
8. Mackness, M.I.; Durrington, P.N.; Mackness, B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am. J. Cardiovasc. Drugs. 2004, 4, 211-217.
9. Mackness, M.I.; Mackness, B.; Durrington, P.N. Paraoxonase and coronary artery disease. Atheroscler. Suppl. 2002, 3, 49-55.
10. Costa, L.G.; Giordano, G.; Cole, T.B.; Marsillach, J.; Furlong, C.E. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 2013, 307, 115-122.
11. Khersonsky, O.; Tawfik, D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44, 6371-6382.
12. Khersonsky, O.; Tawfik, D.S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem. Eur. J. Chem. Biol. 2006, 7, 49-53.
13. Liu, T.; Zhang, X.; Zhang, J.; Liang, Z.; Cai, W.; Huang, M.; Yan, C.; Zhu, Z.; Han, Y. Association between PON1 rs662 polymorphism and coronary artery disease. Eur. J. Clin. Nutr. 2014, 68, 1029-1035.
14. Shekhanawar, M.; Shekhanawar, S.M.; Krisnaswamy, D.; Indumati, V.; Satishkumar, D.; Vijay, V.; Rajeshwari, T.; Amareshwar, M. The role of “paraoxonase-1 activity” as an antioxidant in coronary artery diseases. J. Clin. Diagn. Res. JCDR 2013, 7, 1284-1287.
15. Cozzi, L.; Campolo, J.; Parolini, M.; De Maria, R.; Patrosso, M.C.; Marocchi, A.; Parodi, O.; Penco, S. Paraoxonase 1 L55M, Q192R and paraoxonase 2 S311C alleles in atherothrombosis. Mol. Cell. Biochem. 2013, 374, 233-238.
16. Tang, W.H.W.; Hartiala, J.; Fan, Y.; Wu, Y.; Stewart, A.F.R.; Erdmann, J.; Kathiresan, S.; CARDIoGRAM Consortium; Roberts, R.; McPherson, R.; Allayee, H.; Hazen, S.L. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2803-2812.
17. Bayrak, A.; Bayrak, T.; Tokgözoglu, S.L.; Volkan-Salanci, B.; Deniz, A.; Yavuz, B.; Alikasifoglu, M.; Demirpençe, E. Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis. J. Atheroscler. Thromb. 2012, 19, 376-384.
18. Saxena T; Agarwal B.K.; Kare P. Serum paraoxonase activity and oxidative stress in acute myocardial infarction patients. Biomed. Res. 2011, 22, 215-219.
19. Gluba, A.; Pietrucha, T.; Banach, M.; Piotrowski, G.; Rysz, J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010, 61, 157-165.
20. Lakshmy, R.; Ahmad, D.; Abraham, R.A.; Sharma, M.; Vemparala, K.; Das, S.; Reddy, K.S.; Prabhakaran, D. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J. Med. Res. 2010, 131, 522-529.
21. Regieli, J.J.; Jukema, J.W.; Doevendans, P.A.; Zwinderman, A.H.; Kastelein, J.J.; Grobbee, D.E.; van der Graaf, Y. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol. 2009, 54, 1238-1245.
22. Jayakumari, N.; Thejaseebai, G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J. Clin. Biochem. Nutr. 2009, 45, 278-284.
23. Yildiz, A.; Gur, M.; Yilmaz, R.; Demirbag, R.; Polat, M.; Selek, S.; Celik, H.; Erel, O. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008, 197, 257-263.
24. Saeed, M.; Perwaiz Iqbal, M.; Yousuf, F.A.; Perveen, S.; Shafiq, M.; Sajid, J.; Frossard, P.M. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. Clin. Genet. 2007, 71, 238-244.
25. Jarvik, G.P.; Hatsukami, T.S.; Carlson, C.; Richter, R.J.; Jampsa, R.; Brophy, VH.; Margolin, S.; Rieder, M.; Nickerson, D.; Schellenberg, G.D., et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1465-1471.
26. Domagała, T.B.; Łacinski, M.; Trzeciak, W.H.; Mackness, B.; Mackness, M.I.; Jakubowski, H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell. Mol. Biol. 2006, 52, 4-10.
27. Su, S.; Chen, J.; Huang, J.; Wang, X.; Zhao, J.; Shen, Y.; Qiang, B.; Gu, D. Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. Chin. Med. J. (Engl.) 2005, 118, 1167-1174.
28. Rodríguez-Esparragón, F.; Rodríguez-Pérez, J.C.; Hernández-Trujillo, Y.; Macías-Reyes, A.; Medina, A.; Caballero, A.; Ferrario, C.M. Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 854-860.
29. Kabaroglu, C.; Mutaf, I.; Boydak, B.; Ozmen, D.; Habif, S.; Erdener, D.; Parildar, Z.; Bayindir, O. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta. Cardiol. 2004, 59, 606-611.
30. Srinivasan, S.R.; Li, S.; Chen, W.; Tang, R.; Bond, M.G.; Boerwinkle, E.; Berenson, G.S. Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. Atherosclerosis 2004, 177, 167-174.
31. Göçmen, A.Y.; Gümüşlü, S.; Semiz, E. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin. Cardiol. 2004, 27, 426-430.
32. Oliveira, S.A.; Mansur, A.P.; Ribeiro, C.C.; Ramires, J.A.F.; Annichino-Bizzacchi, J.M. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int. J. Cardiol. 2004, 94, 73-77.
33. Robertson, K.S.; Hawe, E.; Miller, G.J.; Talmud, P.J.; Humphries, S.E. Northwick Park Heart Study II Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim. Biophys. Acta 2003, 1639, 203-212.
34. Wang, X.; Fan, Z.; Huang, J.; Su, S.; Yu, Q.; Zhao, J.; Hui, R.; Yao, Z.; Shen, Y.; Qiang, B.; Gu, D. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 328-334.
35. Fortunato, G.; Rubba, P.; Panico, S.; Trono, D.; Tinto, N.; Mazzaccara, C.; de Michele, M.; Iannuzzi, A.; Vitale, D.F.; Salvatore, F., et al. A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 2003, 167, 141-148.
36. Rahmani, M.; Raiszadeh, F.; Allahverdian, S.; Kiaii, S.; Navab, M.; Azizi, F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002, 162, 381-389.
37. Ferré, N.; Tous, M.; Paul, A.; Zamora, A.; Vendrell, J.J.; Bardají, A.; Camps, J.; Richart, C.; Joven, J. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin. Biochem. 2002, 35, 197-203.
38. Hong, S.H.; Song, J.; Min, W.K.; Kim, J.Q. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin. Biochem. 2001, 34, 475-481.
39. Malin, R.; Järvinen, O.; Sisto, T.; Koivula, T.; Lehtimäki, T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis 2001, 157, 301-307.
40. Gardemann, A.; Philipp, M.; Hess, K.; Katz, N.; Tillmanns, H.; Haberbosch, W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000, 152, 421-431.
41. Cascorbi, I.; Laule, M.; Mrozikiewicz, P.M.; Mrozikiewicz, A.; Andel, C.; Baumann, G.; Roots, I.; Stangl, K. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 1999, 9, 755-761.
42. Sanghera, D.K.; Aston, C.E.; Saha, N.; Kamboh, M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 1998, 62, 36-44.
43. Ombres, D.; Pannitteri, G.; Montali, A.; Candeloro, A.; Seccareccia, F.; Campagna, F.; Cantini, R.; Campa, P.P.; Ricci, G.; Arca, M. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1611-1616.
44. Sanghera, D.K.; Saha, N.; Aston, C.E.; Kamboh, M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 1067-1073.
45. Suehiro, T.; Nakauchi, Y.; Yamamoto, M.; Arii, K.; Itoh, H.; Hamashige, N.; Hashimoto, K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 1996, 57, 69-73.
46. Herrmann, S.M.; Blanc, H.; Poirier, O.; Arveiler, D.; Luc, G.; Evans, A.; Marques-Vidal, P.; Bard, J.M.; Cambien, F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996, 126, 299-303.
47. McElveen, J.; Mackness, M.I.; Colley, C.M.; Peard, T.; Warner, S.; Walker, C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 1986, 32, 671-673.
48. Gaidukov, L.; Tawfik, D.S. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J. Lipid Res. 2007, 48, 1637-1646.
49. Parra, S.; Marsillach, J.; Aragonès, G.; Rull, A.; Beltrán-Debón, R.; Alonso-Villaverde, C.; Joven, J.; Camps, J. Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. Lipids Health Dis. 2010, 9, doi:10.1186/1476-511X-9-32.
50. Aviram, M.; Vaya, J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr. Opin. Lipidol. 2013, 24, 339-344.
51. Furlong, C.E.; Richter, R.J.; Li, W.F.; Brophy, V.H.; Carlson, C.; Rieder, M.; Nickerson, D.; Costa, L.G.; Ranchalis, J.; Lusis, A.J., et al. The functional consequences of polymorphisms in the human PON1 gene. In The paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism; Springer: Dordrecht, The Netherlands, 2008; Volume 6, pp. 267-281.
52. Marsillach, J.; Aragonès, G.; Beltrán, R.; Caballeria, J.; Pedro-Botet, J.; Morcillo-Suárez, C.; Navarro, A.; Joven, J.; Camps, J. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin. Biochem. 2009, 42, 91-98.
53. Camps, J.; Mackness, M.; Mackness, B.; Marsillach, J.; Joven, J. Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results. Clin. Chem. Lab. Med. 2010, 48, 893-894.
54. Marsillach, J.; Camps, J.; Beltran-Debón, R.; Rull, A.; Aragones, G.; Maestre-Martínez, C.; Sabench, F.; Hernández, M.; Castillo, D.D.; Joven, J., et al. Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur. J. Clin. Invest. 2011, 41, 308-314.
55. Fortunato, G.; Di Taranto, M.D.; Bracale, U.M.; Del Guercio, L.; Carbone, F.; Mazzaccara, C.; Morgante, A.; D’Armiento, F.P.; D’Armiento, M.; Porcellini, M., et al. Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 594-600.
56. Tavori, H.; Vaya, J.; Aviram, M. Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv. Exp. Med. Biol. 2010, 660, 99-111.
57. Martinelli, N.; Consoli, L.; Girelli, D.; Grison, E.; Corrocher, R.; Olivieri, O. Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease. Adv. Clin. Chem. 2013, 59, 65-100.
58. Liu, H.; Xia, P.; Liu, M.; Ji, X.M.; Sun, H.B.; Tao, L.; Mu, Q.W. PON gene polymorphisms and ischaemic stroke: a systematic review and meta analysis. Int. J. Stroke 2013, 8, 111-123.
59. Précourt, L.-P.; Amre, D.; Denis, M.-C.; Lavoie, J.-C.; Delvin, E.; Seidman, E.; Levy, E. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011, 214, 20-36.
60. Ng, C.J.; Shih, D.M.; Hama, S.Y.; Villa, N.; Navab, M.; Reddy, S.T. The paraoxonase gene family and atherosclerosis. Free Radic. Biol. Med. 2005, 38, 153-163.